AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ADPT · NASDAQ · Biotechnology

Adaptive Biotechnologies (ADPT)

Provides clonoSEQ residual-disease testing and immune-receptor discovery services.

$27.79

vs last close−0.27 (−0.95%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	38	46	42	43	46	47	52	59	94	72	71	72
Cost of revenue	19	20	18	19	17	18	17	18	18	18	19	21
Gross profit	19	26	24	24	30	29	35	41	76	53	52	51
	70	97	73	71	62	63	65	66	66	66	71	67
Research & development	29	29	30	25	24	23	24	24	24	22	24	19
	41	43	42	38	38	40	40	41	41	44	47	48
Selling & marketing	20	22	22	20	21	22	23	24	23	24	26	26
General & administrative	20	21	20	18	17	18	17	18	18	20	21	21
Other expenses	0	26	0	8	0	0	0	0	0	0	0	0
Operating income	−51	−71	−49	−47	−33	−34	−30	−25	10	−13	−19	−16
	1	2	1	1	1	0	0	−1	−1	−1	−1	−24
Interest income	4	5	4	4	3	3	3	2	2	2	2	2
Interest expense	4	3	3	3	3	3	3	3	3	3	3	3
Other non-operating income	−4	−5	−4	−4	−3	−3	3	−2	−2	−2	−1	0
Income before tax	−50	−69	−48	−46	−32	−34	−30	−26	10	−14	−20	−40
Net income from continuing operations	−50	−69	−48	−46	−32	−34	−30	−26	10	−14	−20	−40
Net income	−50	−69	−48	−46	−32	−34	−30	−26	10	−14	−20	−40
EPS, basic	−$0.35	−$0.48	−$0.33	−$0.31	−$0.22	−$0.23	−$0.20	−$0.17	$0.06	−$0.09	−$0.13	−$0.25
EPS, diluted	−$0.35	−$0.48	−$0.33	−$0.31	−$0.22	−$0.23	−$0.20	−$0.17	$0.06	−$0.09	−$0.13	−$0.25
Weighted average shares, basic	145	145	146	147	148	147	149	152	152	153	156	158
Weighted average shares, diluted	145	145	146	147	148	147	149	152	163	153	156	158
EBITDA	−41	−61	−39	−39	−25	−26	−30	−18	17	−6	−14	−12
Depreciation & amortization	6	5	5	5	5	4	3	5	4	4	4	4
EBIT	−47	−66	−45	−44	−29	−31	−33	−23	13	−11	−18	−16